

An S De Vriese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6987384/publications.pdf>

Version: 2024-02-01

120
papers

8,536
citations

61687

45
h-index

51423

90
g-index

122
all docs

122
docs citations

122
times ranked

9264
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2072-2079.	0.4	28
2	Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registry. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1361-1372.	1.4	5
3	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	2.6	82
4	Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1103-1107.	0.4	8
5	Acute glomerulonephritis. <i>Lancet, The</i> , 2022, 399, 1646-1663.	6.3	24
6	Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 385-396.	3.0	101
7	PEXIVAS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 307-309.	2.2	6
8	A Target Antigen-Based Approach to the Classification of Membranous Nephropathy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 577-591.	1.4	45
9	Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1474-1483.	3.0	87
10	Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents. <i>Clinical Infectious Diseases</i> , 2021, 73, 2145-2147.	2.9	62
11	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2390-2391.	3.0	0
12	Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2446-2448.	1.4	5
13	Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3208-3220.	3.0	74
14	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1833-1839.	2.2	27
15	Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 23-33.	0.4	31
16	IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 440-441.	2.1	33
17	In Reply to "Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?" TM . <i>American Journal of Kidney Diseases</i> , 2020, 76, 598-599.	2.1	0
18	Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 186-196.	3.0	116

#	ARTICLE	IF	CITATIONS
19	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	2.6	7
20	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. <i>Kidney International</i> , 2019, 95, 429-438.	2.6	123
21	Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 759-774.	3.0	186
22	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2018, 93, 991-1008.	1.4	82
23	Measurement of pulse wave velocity, augmentation index, and central pulse pressure in atrial fibrillation: a proof of concept study. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 627-632.	2.3	13
24	Other consequences from monoclonal immunoglobulins/fragments. , 2018, , .		0
25	Should Statins Be Banned from Dialysis?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1675-1676.	3.0	21
26	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i14-i21.	0.4	15
27	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i139-i145.	0.4	59
28	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. <i>Kidney International</i> , 2017, 91, 787-789.	2.6	161
29	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	1.4	15
30	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1772-1781.	1.4	39
31	A Proposal for a Serology-Based Approach to Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 421-430.	3.0	273
32	Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2017, 184, 37-46.	1.2	81
33	P143 VALIDITY OF PULSE WAVE VELOCITY AND AUGMENTATION INDEX MEASUREMENTS IN PATIENTS WITH ATRIAL FIBRILLATION. <i>Artery Research</i> , 2017, 20, 96.	0.3	0
34	Fibromuscular dysplasia - results of a multicentre study in Flanders. <i>Vasa - European Journal of Vascular Medicine</i> , 2017, 46, 211-218.	0.6	13
35	Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings. <i>Clinical Nephrology</i> , 2017, 88, 277-283.	0.4	7
36	Diagnosis of complement alternative pathway disorders. <i>Kidney International</i> , 2016, 89, 278-288.	2.6	74

#	ARTICLE	IF	CITATIONS
37	The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. CKJ: Clinical Kidney Journal, 2016, 9, 273-279.	1.4	77
38	The atrial fibrillation conundrum in dialysis patients. American Heart Journal, 2016, 174, 111-119.	1.2	26
39	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	3.0	210
40	C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?. Journal of Nephrology, 2016, 29, 203-209.	0.9	18
41	High homocysteine induces betaine depletion. Bioscience Reports, 2015, 35, .	1.1	20
42	Con: Biomarkers in glomerular diseases: putting the cart before the wheel?. Nephrology Dialysis Transplantation, 2015, 30, 885-890.	0.4	6
43	In Reply to "Hemodialysis Catheters: Which Design Is More Cost-effective?" and "Use of an Uncensored Primary Outcome in a Catheter Design Trial?". American Journal of Kidney Diseases, 2015, 66, 171.	2.1	0
44	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	3.0	84
45	Dose-Finding Study of Rivaroxaban in Hemodialysis Patients. American Journal of Kidney Diseases, 2015, 66, 91-98.	2.1	119
46	C4d as a Diagnostic Tool in Proliferative GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2852-2859.	3.0	106
47	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 898-899.	0.4	1
48	Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrology Dialysis Transplantation, 2014, 29, 1385-1390.	0.4	105
49	A Bone Scan, No Mistake!. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4447-4448.	1.8	0
50	Hemodialysis Catheter Design and Catheter Performance: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2014, 64, 902-908.	2.1	48
51	Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1708-1714.	1.8	33
52	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. Journal of the American Society of Nephrology: JASN, 2013, 24, 1981-1994.	3.0	96
53	Should we screen for coronary artery disease in asymptomatic chronic dialysis patients?. Kidney International, 2012, 81, 143-151.	2.6	36
54	Reversion of cerebral artery stenoses due to tuberculomas with TNF- α antibodies. Clinical Neurology and Neurosurgery, 2012, 114, 1016-1018.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Vancomycin Dosing in Patients on Intermittent Hemodialysis. <i>Seminars in Dialysis</i> , 2011, 24, 50-55.	0.7	39
56	Diffuse Alveolar Hemorrhage Induced by Everolimus. <i>Chest</i> , 2010, 137, 456-459.	0.4	36
57	Recent changes in vancomycin use in renal failure. <i>Kidney International</i> , 2010, 77, 760-764.	2.6	84
58	Indications to Start Kidney Replacement Therapy. , 2010, , 471-479.		0
59	Staphylococcus aureus Infections in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1388-1400.	2.2	100
60	Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in hemodialysis patients. <i>Kidney International</i> , 2009, 76, 428-436.	2.6	10
61	Oral Vitamin C Administration Increases Lipid Peroxidation in Hemodialysis Patients. <i>Nephron Clinical Practice</i> , 2008, 108, c28-c34.	2.3	18
62	Renal side effects of anti-VEGF therapy in man: a new test system. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2778-2780.	0.4	19
63	Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1330-1335.	0.4	26
64	Prevention of contrast-induced nephropathy: a critical review. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 336-347.	1.0	43
65	Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study. <i>Journal of Hepatology</i> , 2007, 46, 804-815.	1.8	5
66	Steroid-resistant sarcoidosis: is antagonism of TNF- α the answer?. <i>Clinical Science</i> , 2007, 112, 281-289.	1.8	44
67	Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1111-1117.	2.9	270
68	Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. <i>Liver International</i> , 2006, 26, 889-898.	1.9	65
69	Effects of Peritoneal Dialysis on the Vascular Bed of Peritoneal Membrane. , 2006, 150, 84-89.		3
70	A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 324-329.	0.4	65
71	Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3364-3367.	0.4	44
72	Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2549-2555.	0.4	122

#	ARTICLE	IF	CITATIONS
73	Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. <i>Kidney International</i> , 2005, 67, 1559-1565.	2.6	99
74	The John F. Maher Recipient Lecture 2004: Rage in the Peritoneum. <i>Peritoneal Dialysis International</i> , 2005, 25, 8-11.	1.1	18
75	Animal Models in Peritoneal Dialysis Research: A Need for Consensus. <i>Peritoneal Dialysis International</i> , 2005, 25, 16-24.	1.1	28
76	Effects of New Peritoneal Dialysis Solutions on Leukocyte Recruitment in the Rat Peritoneal Membrane. <i>Nephron Experimental Nephrology</i> , 2005, 101, e139-e145.	2.4	24
77	Pathophysiological Role of Vascular Endothelial Growth Factor in the Remnant Kidney. <i>Nephron Experimental Nephrology</i> , 2005, 101, e9-e15.	2.4	31
78	Immunopathological changes in a uraemic rat model for peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1350-1361.	0.4	38
79	Analytical and biochemical aspects associated with supraphysiological creatine intake. <i>Clinica Chimica Acta</i> , 2005, 351, 217-219.	0.5	4
80	Cytochrome P450-2C11 mRNA Is Not Expressed in Endothelial Cells Dissected from Rat Renal Arterioles. <i>Nephron Physiology</i> , 2005, 99, p43-p49.	1.5	2
81	The Effects of Peritoneal Dialysis Solutions on Peritoneal Host Defense. <i>Peritoneal Dialysis International</i> , 2004, 24, 123-138.	1.1	55
82	Endothelium-Derived Hyperpolarizing Factor Mediated Renal Vasodilatory Response Is Impaired During Acute and Chronic Hyperhomocysteinemia. <i>Circulation</i> , 2004, 109, 2331-2336.	1.6	62
83	Prohepcidin accumulates in renal insufficiency. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 387-9.	1.4	80
84	Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1092-1097.	0.4	29
85	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. <i>Liver International</i> , 2004, 24, 63-68.	1.9	35
86	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. <i>Kidney International</i> , 2004, 65, 2003-2017.	2.6	411
87	Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. <i>Kidney International</i> , 2004, 66, 1257-1265.	2.6	171
88	Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. <i>Kidney International</i> , 2004, 66, 2422-2428.	2.6	26
89	From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines. <i>Endocrine Reviews</i> , 2004, 25, 971-1010.	8.9	309
90	Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 139-145.	0.8	28

#	ARTICLE	IF	CITATIONS
91	Renal angiomyolipoma in association with pulmonary lymphangiomyomatosis. American Journal of Kidney Diseases, 2003, 41, 877-883.	2.1	24
92	Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney International, 2003, 64, 1331-1337.	2.6	39
93	Sildenafil in rats with cirrhosis and portal hypertension: Systemic and splanchnic haemodynamic effects. Gastroenterology, 2003, 124, A736.	0.6	0
94	Prevention and Treatment of Acute Renal Failure in Sepsis. Journal of the American Society of Nephrology: JASN, 2003, 14, 792-805.	3.0	115
95	Effects of Conventional and New Peritoneal Dialysis Fluids on Leukocyte Recruitment in the Rat Peritoneal Membrane. Journal of the American Society of Nephrology: JASN, 2003, 14, 1296-1306.	3.0	86
96	Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2596-2600.	0.4	33
97	The emerging role of VEGF in diabetic kidney disease. Nephrology Dialysis Transplantation, 2003, 18, 1427-1430.	0.4	36
98	Pharmacologic treatment of acute renal failure in sepsis. Current Opinion in Critical Care, 2003, 9, 474-480.	1.6	27
99	Prevention and nondialytic treatment of acute renal failure. Current Opinion in Critical Care, 2003, 9, 481-490.	1.6	58
100	Recent Concepts in the Molecular Biology of the Peritoneal Membrane – Implications for More Biocompatible Dialysis Solutions. Blood Purification, 2003, 21, 14-23.	0.9	39
101	Peritoneal Microcirculation. , 2003, 140, 56-69.		4
102	Factors influencing the progression of diabetic nephropathy. , 2003, , 75-96.		0
103	Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody. Diabetes, 2002, 51, 3090-3094.	0.3	288
104	The Effects of Heparin Administration in an Animal Model of Chronic Peritoneal Dialysate Exposure. Peritoneal Dialysis International, 2002, 22, 566-572.	1.1	29
105	Increased Leukocyte Rolling in Newly Formed Mesenteric Vessels in the Rat during Peritoneal Dialysis. Peritoneal Dialysis International, 2002, 22, 655-662.	1.1	18
106	Interesting News in Peritoneal Dialysis. Nephron, 2002, 92, 763-771.	0.9	0
107	Effects of connexin-mimetic peptides on nitric oxide synthase- and cyclooxygenase-independent renal vasodilation. Kidney International, 2002, 61, 177-185.	2.6	70
108	Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?. Kidney International, 2002, 61, 1199-1209.	2.6	39

#	ARTICLE	IF	CITATIONS
109	Experimental diabetes induces functional and structural changes in the peritoneum. <i>Kidney International</i> , 2002, 62, 668-678.	2.6	31
110	What Happens to the Peritoneal Membrane in Long-Term Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2001, 21, 9-18.	1.1	46
111	Non Anticoagulant Effects of Heparin: Implications for Animal Models of Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2001, 21, 354-356.	1.1	12
112	Intravital microscopy: an integrated evaluation of peritoneal function and structure. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 657-660.	0.4	17
113	Neovascularization in the peritoneal membrane: does it play a role in ultrafiltration failure?. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2143-2145.	0.4	17
114	Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: Role of nitric oxide. <i>Kidney International</i> , 2001, 60, 202-210.	2.6	55
115	Glucotoxicity of the peritoneal membrane: the case for VEGF. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2299-2302.	0.4	15
116	Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 993-1000.	3.0	394
117	Vascular Endothelial Growth Factor Is Essential for Hyperglycemia-Induced Structural and Functional Alterations of the Peritoneal Membrane. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1734-1741.	3.0	147
118	Endothelial dysfunction in diabetes. <i>British Journal of Pharmacology</i> , 2000, 130, 963-974.	2.7	966
119	Off-Line Analysis of Red Blood Cell Velocity in Renal Arterioles. <i>Journal of Vascular Research</i> , 2000, 37, 26-31.	0.6	45
120	Influence of vasoactive intestinal polypeptide and NGnitro-L-arginine methyl ester on cholinergic neurotransmission in the rat gastric fundus. <i>European Journal of Pharmacology</i> , 1992, 221, 235-242.	1.7	44